Rock Springs Capital Management LP boosted its holdings in Abcam plc (NASDAQ:ABCM – Get Rating) by 14.4% during the first quarter, Holdings Channel reports. The institutional investor owned 1,432,900 shares of the company's stock after buying an additional 180,400 shares during the period. Rock Springs Capital Management LP's holdings in Abcam were worth $26,208,000 at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in ABCM. Advisor Group Holdings Inc. raised its holdings in shares of Abcam by 20.5% in the 4th quarter. Advisor Group Holdings Inc. now owns 5,876 shares of the company's stock worth $138,000 after purchasing an additional 999 shares during the period. TD Asset Management Inc. raised its holdings in shares of Abcam by 63.0% in the 4th quarter. TD Asset Management Inc. now owns 72,773 shares of the company's stock worth $1,714,000 after purchasing an additional 28,130 shares during the period. Jarislowsky Fraser Ltd raised its holdings in shares of Abcam by 0.5% in the 4th quarter. Jarislowsky Fraser Ltd now owns 315,129 shares of the company's stock worth $7,421,000 after purchasing an additional 1,677 shares during the period. Bank of Montreal Can raised its holdings in shares of Abcam by 0.9% in the 4th quarter. Bank of Montreal Can now owns 105,928 shares of the company's stock worth $2,525,000 after purchasing an additional 956 shares during the period. Finally, 2Xideas AG purchased a new position in shares of Abcam in the 4th quarter worth about $16,691,000. 11.82% of the stock is owned by institutional investors and hedge funds.
Get
Abcam alerts:
Abcam Stock Performance
Shares of NASDAQ:ABCM traded up $0.07 during mid-day trading on Tuesday, hitting $15.77. 304 shares of the company traded hands, compared to its average volume of 173,803. Abcam plc has a 52-week low of $12.54 and a 52-week high of $24.00. The firm's 50 day simple moving average is $14.81 and its 200 day simple moving average is $15.54.
Analysts Set New Price Targets
Separately, Panmure Gordon upgraded Abcam from a "hold" rating to a "buy" rating in a report on Monday, September 5th.
Abcam Company Profile
(Get Rating)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools.
Further Reading
- Get a free copy of the StockNews.com research report on Abcam (ABCM)
- The Two Things You Need To Know About Oracle's FQ1 Report
- Three Value Stocks For A Volatile Market
- 3 Energy Stocks Nearing Breakouts From Cup-Shaped Patterns
- Do These Dividend Achievers Deserve A Place In Your Portfolio?
- Darden Restaurants Takes the Low Road Against Inflation
Want to see what other hedge funds are holding ABCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abcam plc (NASDAQ:ABCM – Get Rating).
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.
